Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

“Tegoprazan offers an exciting new treatment option for individuals suffering from GERD, helping to address the substantial unmet need of patients not well-controlled by conventional PPI therapy,” ...

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

FDA to establish national standard and timeline for food industry to transition from petrochemical-based dyes to natural alternatives.

Meanwhile, a new registry is being created to track those with autism, and that information will be part of the database.

Both the FDA and Novo Nordisk are advising patients and providers to check their supplies of Ozempic for counterfeit product.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to BA-102 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder linked to autism.

Dr David Sugerman, a senior scientist at the CDC, said that the agency is "scraping to find the resources" to support states affected by the outbreaks.

The FDA issues alert regarding compounded topical finasteride; plant-based alkaloid shows improvements for smoking cessation; potential new treatment option for GERD; and the CDC’s Advisory Committee ...

HealthDay News — A single-dose baloxavir treatment can reduce influenza transmission from index patients to household contacts, according to a study published in the April 24 issue of the New England ...

Threats include increasing demand, patients with increasingly complex needs, and falling payments for physicians.

After 3 initial monthly injections, current dosing intervals range from every 8 to 16 weeks in patients with wAMD and DME and every 8 to 12 weeks in patients with DR.